Evidence map›Paper›PMID 28222742›Full record

Trial reportNutrition journal2017

Resistant starch lowers postprandial glucose and leptin in overweight adults consuming a moderate-to-high-fat diet: a randomized-controlled trial.

Mindy Patterson Maziarz, Sara Preisendanz, Shanil Juma, Victorine Imrhan, Chandan Prasad, Parakat Vijayagopal

Open access · goldAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Nutrition journal, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
34citing papers in PubMed, 4 pooled it
3.6field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

34 citing papers in PubMed, 4 syntheses or guidelines pooled it, 80 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Trial
  6. Trial
  7. Trial
  8. Trial
  9. Trial
  10. Trial
  11. Review
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Nutrition, Pregnancy, and Preexisting Diabetes: Exploring What Has Changed and What Remains the Same.Diabetes spectrum : a publication of the American Diabetes Association · 2025
    Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Mindy Patterson MaziarzDepartment of Nutrition and Food Sciences, Institute of Health Sciences, Texas Woman's University, 6700 Fannin Street, Houston, TX, 77030, USA.
Sara PreisendanzDepartment of Nutrition and Food Sciences, Texas Woman's University, P.O Box 425888, Denton, TX, 76204, USA.
Shanil JumaDepartment of Nutrition and Food Sciences, Texas Woman's University, P.O Box 425888, Denton, TX, 76204, USA.
Victorine ImrhanDepartment of Nutrition and Food Sciences, Texas Woman's University, P.O Box 425888, Denton, TX, 76204, USA.
Chandan PrasadDepartment of Nutrition and Food Sciences, Texas Woman's University, P.O Box 425888, Denton, TX, 76204, USA.
Parakat VijayagopalDepartment of Nutrition and Food Sciences, Texas Woman's University, P.O Box 425888, Denton, TX, 76204, USA. pvijayagopal@twu.edu.ORCID 0000-0003-0791-2312
Texas Woman's University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundHigh-amylose maize resistant starch type 2 (HAM-RS2) stimulates gut-derived satiety peptides and reduces adiposity in animals. Human studies have not supported these findings despite improvements in glucose homeostasis and insulin sensitivity after HAM-RS2 intake which can lower adiposity-related disease risk. The primary objective of this study was to evaluate the impact of HAM-RS2 consumption on blood glucose homeostasis in overweight, healthy adults. We also examined changes in biomarkers of satiety (glucagon-like peptide-1 [GLP-1], peptide YY [PYY], and leptin) and body composition determined by anthropometrics and dual-energy x-ray absorptiometry, dietary intake, and subjective satiety measured by a visual analogue scale following HAM-RS2 consumption.

methodsUsing a randomized-controlled, parallel-arm, double-blind design, 18 overweight, healthy adults consumed either muffins enriched with 30 g HAM-RS2 (n = 11) or 0 g HAM-RS2 (control; n = 7) daily for 6 weeks. The HAM-RS2 and control muffins were similar in total calories and available carbohydrate.

resultsAt baseline, total PYY concentrations were significantly higher 120 min following the consumption of study muffins in the HAM-RS2 group than control group (P = 0.043). Within the HAM-RS2 group, the area under the curve (AUC) glucose (P = 0.028), AUC leptin (P = 0.022), and postprandial 120-min leptin (P = 0.028) decreased independent of changes in body composition or overall energy intake at the end of 6 weeks. Fasting total PYY increased (P = 0.033) in the HAM-RS2 group, but changes in insulin or total GLP-1 were not observed. Mean overall change in subjective satiety score did not correlate with mean AUC biomarker changes suggesting the satiety peptides did not elicit a satiation response or change in overall total caloric intake. The metabolic response from HAM-RS2 occurred despite the habitual intake of a moderate-to-high-fat diet (mean range 34.5% to 39.4% of total calories).

conclusionConsuming 30 g HAM-RS2 daily for 6 weeks can improve glucose homeostasis, lower leptin concentrations, and increase fasting PYY in healthy overweight adults without impacting body composition and may aid in the prevention of chronic disease. However, between-group differences in biomarkers were not observed and future research is warranted before specific recommendations can be made.

trial registrationNone.

Indexed as

Diet, High-FatPostprandial PeriodAbsorptiometry, PhotonAdiposityAdolescentAdultBiomarkersBlood GlucoseDouble-Blind MethodFemaleGlucagon-Like Peptide 1HumansInsulinInsulin ResistanceLeptinMaleBiomarkersBlood GlucoseGlucagon-Like Peptide 1InsulinLeptinPeptide YYStarchFiberGut peptidesLeptinOverweightPYYResistant starchSatiety

Identifiers

PMID28222742
PMCPMC5320660
OpenAlexW2590553737

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.